prikaz prve stranice dokumenta ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
  Preuzmi
PDF 904.43 KB
Znanstveni rad - Prethodno/kratko priopćenje
ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
European Journal of Immunology, 52 (2022), 6; 936-945. https://doi.org/10.1002/eji.202249823
Cokarić Brdovčak, Maja; Materljan, Jelena; Šustić, Marko; Ravlić, Sanda; Ružić, Tina; Lisnić, Berislav; Miklić, Karmela; Brizić, Ilija; Pribanić Matešić, Marina; Juranić Lisnić, Vanda; Halassy, Beata; Rončević, Dobrica; Knežević, Zdravka; Štefan, Leo; Bertoglio, Federico; Schubert, Maren; Čičin‐Šain, Luka; Markotić, Alemka; Jonjić, Stipan; Krmpotić, Astrid Više autora...

Povezani objekti
COVID-19 (zbirka 2.) | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Cokarić Brdovčak, M., Materljan, J., Šustić, M., Ravlić, S., Ružić, T., Lisnić, B. ... Krmpotić, A. (2022). ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology, 52. (6), 936-945. doi: 10.1002/eji.202249823

Cokarić Brdovčak, Maja, et al. "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination." European Journal of Immunology, vol. 52, br. 6, 2022, str. 936-945. https://doi.org/10.1002/eji.202249823

Cokarić Brdovčak, Maja, Jelena Materljan, Marko Šustić, Sanda Ravlić, Tina Ružić, Berislav Lisnić, Karmela Miklić, et al. "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination." European Journal of Immunology 52, br. 6 (2022): 936-945. https://doi.org/10.1002/eji.202249823

Cokarić Brdovčak, M., et al. (2022) 'ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination', European Journal of Immunology, 52(6), str. 936-945. doi: 10.1002/eji.202249823

Cokarić Brdovčak M, Materljan J, Šustić M, Ravlić S, Ružić T, Lisnić B, i sur.. ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology [Internet]. 31.03.2022. [pristupljeno 23.12.2024.];52(6):936-945. doi: 10.1002/eji.202249823

M. Cokarić Brdovčak, et al., "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination", European Journal of Immunology, vol. 52, br. 6, str. 936-945, Ožujak 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:945601. [Citirano: 23.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:945601
Podaci o radu
Naslov (engleski)ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
AutorMaja Cokarić Brdovčak
AutorJelena Materljan
AutorMarko Šustić https://orcid.org/0000-0001-8213-0578
AutorSanda Ravlić
AutorTina Ružić
AutorBerislav Lisnić
AutorKarmela Miklić
AutorIlija Brizić
AutorMarina Pribanić Matešić
AutorVanda Juranić Lisnić
AutorBeata Halassy
AutorDobrica Rončević
AutorZdravka Knežević
AutorLeo Štefan
AutorFederico Bertoglio
AutorMaren Schubert
AutorLuka Čičin‐Šain
AutorAlemka Markotić
AutorStipan Jonjić
AutorAstrid Krmpotić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Imunologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
COVID‐19 vaccines prevent severe forms of the disease, but do not warrant complete protection against breakthrough infections. This could be due to suboptimal mucosal immunity at the site of virus entry, given that all currently approved vaccines are administered via the intramuscular route. In this study, we assessed humoral and cellular immune responses in BALB/c mice after intranasal and intramuscular immunization with adenoviral vector ChAdOx1‐S expressing full‐length Spike protein of SARS‐CoV‐2. We showed that both routes of vaccination induced a potent IgG antibody response, as well as robust neutralizing capacity, but intranasal vaccination elicited a superior IgA antibody titer in the sera and in the respiratory mucosa. Bronchoalveolar lavage from intranasally immunized mice efficiently neutralized SARS‐CoV‐2, which has not been the case in intramuscularly immunized group. Moreover, substantially higher percentages of epitope‐specific CD8 T cells exhibiting a tissue resident phenotype were found in the lungs of intranasally immunized animals. Finally, both intranasal and intramuscular vaccination with ChAdOx1‐S efficiently protected the mice after the challenge with recombinant herpesvirus expressing the Spike protein. Our results demonstrate that intranasal application of adenoviral vector ChAdOx1‐S induces superior mucosal immunity and therefore could be a promising strategy for putting the COVID‐19 pandemic under control.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Immunology
Brojčani podacivol. 52, br. 6, str. 936-945
p-ISSN0014-2980
e-ISSN1521-4141
DOIhttps://doi.org/10.1002/eji.202249823
URN:NBNurn:nbn:hr:184:945601
Datum objave publikacije2022-03-31
ProjektŠifra: IP-CORONA-2020-04-2073
Naziv (hrvatski): Dosta skrivanja CoV-2: uspostava baze monoklonskih protutijela na SARS-Cov-2
Naziv (engleski): No more hiding CoV-2: Establishment of SARS-Cov-2 mAbeom
Kratica: CoV2mAbs
Voditelj: Ilija Brizić
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP-CORONA
ProjektŠifra: IP-CORONA-2020-04-2053
Naziv (hrvatski): Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj
Voditelj: Beata Halassy
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP-CORONA
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1002/eji.202249823
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-06-23 12:08:36